-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Lymphoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Osteosarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Ewing Sarcoma Drug Details: Surufatinib (Sulanda) is a potential...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Rhabdomyosarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Non-Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Non-Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Non-Rhabdomyosarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Solid Tumor Drug Details: Surufatinib (Sulanda) is a potential...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Soft Tissue Sarcoma Drug Details: Surufatinib (Sulanda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Peritoneal Cancer Drug Details: Surufatinib (Sulanda) is a potential...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-4830 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-4830 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-4830 in Squamous Non-Small Cell Lung Cancer Drug...
-
Company Insights
Innovation and Patenting activity of Hutchison Telecommunications Hong Kong Holdings Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hutchison Telecommunications Hong Kong Holdings Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...